| Literature DB >> 30796247 |
Rina Sasaki1, Reina Tainaka1, Yuichi Ando1, Yurika Hashi1,2, Hadya V Deepak3, Yoshiko Suga3, Yuta Murai3, Masaki Anetai3, Kenji Monde3, Kiminori Ohta4,5, Ikuko Ito6, Haruhisa Kikuchi6, Yoshiteru Oshima6, Yasuyuki Endo4, Hitomi Nakao7, Masafumi Sakono7, Koji Uwai1, Kiyotaka Tokuraku8.
Abstract
Protein aggregation is the principal component of numerous protein misfolding pathologies termed proteinopathies, such as Alzheimer's disease, Parkinson's disease, prion disease, and AA amyloidosis with unmet treatment needs. Protein aggregation inhibitors have great potential for the prevention and treatment of proteinopathies. Here we report the development of an automated real-time microliter-scale high throughput screening (MSHTS) system for amyloid aggregation inhibitors using quantum-dot nanoprobes. Screening 504 crude extracts and 134 low molecular weight aromatic compounds revealed the relationship of amyloid-β (Aβ) aggregation inhibitory activities of plant extracts using a plant-based classification. Within the eudicots, rosids, Geraniales and Myrtales showed higher activity. Screening low molecular weight aromatic compounds demonstrated that the structure of tropolone endows it with potential Aβ aggregation inhibitory activity. The activity of the most active tropolone derivative was higher than that of rosmarinic acid. MSHTS also identified three chaperone molecules as tau aggregation inhibitors. These results demonstrate that our automated MSHTS system is a novel and robust tool that can be adapted to a wide range of compounds and aggregation-prone polypeptides.Entities:
Year: 2019 PMID: 30796247 PMCID: PMC6384891 DOI: 10.1038/s41598-019-38958-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Development of the automated MSHTS system. (a) Fluorescence spectrums of QD 605/655 (top) and absorption spectrum of a typical plant (Rosa rugosa) extract. (b) Concentration-dependent Aβ aggregation. Various concentrations of Aβ42 and 30 nM QDAβ were incubated in a 1536-well plate at 37 °C for 24 h, then SD values were determined from fluorescence micrograph images. (c) Fluorescence micrographs acquired under various exposure conditions (top) and the histograms of fluorescence intensities of each pixel (bottom). Bright condition (left, exposure time = 2.0 s), optimum condition (middle, auto exposure), and dark condition (right, exposure time = 100 ms). (d) Relationship between number of pipetting steps and Aβ aggregation inhibitory activity by rosmarinic acid. (e) A scheme of the MSHTS system of Aβ aggregation inhibitors. (f,g) Validation of the automated MSHTS system. SD values of fluorescence images before (0 h) and after (24 h) incubation without inhibitors (f). EC50 values of rosmarinic acid determined using a 1536-well plate (Supplementary Fig. S6).
Figure 2Ranking of 504 natural plant extracts for Aβ aggregation inhibitory activity. (a) Plant list showing EC50 values of 0.05 mg/ml or less (approximately top 10% activity). The number shows the rank of Aβ aggregation inhibitory activity. Activity with an EC50 value of 0.018 mg/ml (EC50 value of spearmint was the highest among the 52 spices[19]) or less is indicated in red while activity in the range of 0.018 to 0.05 mg/ml is indicated in yellow. (b) Order- and family-level analysis using the APG system. The percentage of highly active species included in each plant group is indicated as a red gradation.
Figure 3Screening of low molecular weight aromatic compounds. (a) Initial screening of the compound library. The horizontal axis represents sample number and the vertical axis represents the reciprocal EC50 values. Among the 98 tested samples, 13 samples showed Aβ aggregation inhibitory activity. Seven of these had a tropolone structure (orange bars). (b) Structure and activity of compounds showing EC50 values of 200 µM or less by the MSHTS system. (MA) and (TA) show EC50 values estimated by the MSHTS system and ThT assay, respectively. Compounds surrounded by a dotted orange line are compounds containing a tropolone structure. (c) Second screening of tropolone derivatives. (d–g) Comparison of Aβ aggregation inhibitory activity of tropolone derivatives with similar structures.
Figure 4Imaging of tau aggregation and evaluation of aggregation inhibitory activity of chaperones. (a) Schematic structures of tau and tau MBD used in this study. (b) TEM images of tau and Aβ aggregates. (c) 2D imaging of tau and Aβ aggregation processes using QDTau and QDAβ. (d) TEM image of tau and Aβ aggregates with QD nanoprobes. (e) 3D time lapse imaging of tau and Aβ aggregation by confocal microscopy. (f) 2D images of tau and Aβ aggregates. (g) Percent of SD values determined by 2D image of (c). (h) Inhibitory activity of chaperone, CRT, ERp57, and PDI, for tau and Aβ aggregation (fluorescence images show Supplementary Fig. S12).